A significant reduction in appetite and food intake was also observed with tirzepatide compared to placebo in people with T2D [45]
The intention was to see what retatrutide alone could do versus intensive diet and exercise regimen
and has served on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk
The information, including but not limited to, test, graphics, imagines and other material contained on this website are for informational/educational purposes only
Lastly, the long-term safety profile of semaglutide requires further research to fully understand long-term risks and benefits (Davies et al., 2021)